MONTPELLIER, France, May 03, 2016 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced the first surgical operation with the ROSA™ Spine in the U.S. was performed at Miami Valley Hospital, a nationally recognized medical facility in Dayton, Ohio. Miami Valley Hospital was the first site to acquire ROSA™ Spine in the U.S. following FDA clearance in January 2016.
The operation was performed by Dr. Juan Torres-Reveron, a neurosurgeon at Miami Valley Hospital. The patient presented symptoms associated with ongoing lumbar and leg pain and was treated with a spinal fusion procedure utilizing ROSA™ Spine.
“Premier Health has long been a leader in bringing these advanced technologies to patients," said Mark Shaker, president and Chief Executive Officer of Miami Valley Hospital. "We are extremely proud of our team of highly trained clinicians including physicians, nurses, other professionals, and support staff all working together to provide this level of care for the region."
ROSA™ Spine was granted FDA clearance in the U.S. in January 2016, and received the CE Mark in 2014. Medtech’s ROSA™ Brain received FDA approval in 2012 and is currently in use in 29 U.S. facilities.
“We are proud to officially have ROSA™ Spine in use in the U.S.,” said Bertin Nahum, CEO and founder of Medtech. “This technology allows surgeons to perform minimally invasive surgical procedures on the spine and increases the safety and reliability of the operations. The American market is the world’s leading market for spinal surgery, and this expansion will allow us to benefit a greater number of patients.”
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.